Trial intelligence / Profile preview

Phase III trial of bevacizumab + temozolomide + radiotherapy in newly diagnosed glioblastoma

2008-006146-26Phase 3Completed

Sponsor
Roche
Start
Mar 2009
Modality
Monoclonal Antibodies → Antibody-Based Therapeutics
Countries
1
01

Overview

Phase 3, randomised, double-blind trial in glioblastoma (GBM) comparing Bevacizumab arm with Placebo arm (2 arms). Primary endpoint: Overall survival. Started Mar 2009; status: completed.

02

Drugs

bevacizumab
03

Conditions

glioblastoma (GBM)

Beyond the preview

Go deeper on 2008-006146-26.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2008-006146-26.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call